Literature DB >> 9684155

The importance of bacterial infections as precipating factors of chronic hepatic encephalopathy in cirrhosis.

E Strauss1, M F da Costa.   

Abstract

BACKGROUND/AIMS: It is generally accepted that chronic hepatic encephalopathy (HE) is a stable form of neuropsychiatric disorder, usually related to porto-systemic shunts and with no exogenous precipitating factors. Bacterial infections are frequent causes of morbidity in cirrhosis, including the development of HE in its acute form, but there are no reports of its role in chronic forms of HE.
METHODOLOGY: We studied 168 episodes of hepatic encephalopathy in 111 patients with cirrhosis who were admitted to hospital during the last four years. Clinical staging was used for the diagnosis of acute and chronic HE, complemented by number connection tests and EEG. In chronic HE the diagnostic criteria were intolerance to animal proteins and a continuous need for medications and/or special diets. Alcohol was the etiology of cirrhosis in 81.1% of patients, hepatitis B or C virus in 12.6% and various factors in 6.3%. The male/female ratio was 3:1 and mean age was 53 years.
RESULTS: Twenty patients (18%) were characterized as having chronic HE, whereas ninety-one (82%) presented acute HE. Precipitating factors could be detected in 43 out of 57 (75.4%) of chronic forms and in 108 of 111 (97.3%) episodes of acute HE. Bacterial infections were associated with HE in 15 of 43 cases (34.8%) of chronic HE and in 37 of 108 (34.7%) cases of acute HE (p < 0.05). Spontaneous bacterial peritonitis was the most prevalent infection in acute HE, whereas urinary tract infection was most frequent in chronic HE. Mortality was higher in acute than in chronic HE (p < 0.001), associated with Child C prognostic classification, grades III and IV of HE and more severe precipitating factors.
CONCLUSIONS: The diagnosis and control of precipitating factors, especially bacterial infection, should also be considered during the treatment of chronic hepatic encephalopathy.

Entities:  

Mesh:

Year:  1998        PMID: 9684155

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  11 in total

1.  Neostigmine for the treatment of acute hepatic encephalopathy with acute intestinal pseudo-obstruction in a cirrhotic patient.

Authors:  Chang Hwan Park; Young Eun Joo; Hyun Soo Kim; Sung Kyu Choi; Jong Sun Rew; Sei Jong Kim
Journal:  J Korean Med Sci       Date:  2005-02       Impact factor: 2.153

2.  Current concepts in the pathophysiology and management of hepatic encephalopathy.

Authors:  R Todd Frederick
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-04

Review 3.  Irritable bowel syndrome: a microbiome-gut-brain axis disorder?

Authors:  Paul J Kennedy; John F Cryan; Timothy G Dinan; Gerard Clarke
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

4.  Managing complications in cirrhotic patients.

Authors:  Markus Peck-Radosavljevic; Paolo Angeli; Juan Cordoba; Oliver Farges; Dominique Valla
Journal:  United European Gastroenterol J       Date:  2015-02       Impact factor: 4.623

5.  Vigilance and wake EEG architecture in simulated hyperammonaemia: a pilot study on the effects of L-Ornithine-L-Aspartate (LOLA) and caffeine.

Authors:  Maria Garrido; Jelena Skorucak; Daniela Raduazzo; Matteo Turco; Giuseppe Spinelli; Paolo Angeli; Piero Amodio; Peter Achermann; Sara Montagnese
Journal:  Metab Brain Dis       Date:  2016-05-19       Impact factor: 3.584

Review 6.  Therapeutic studies in hepatic encephalopathy.

Authors:  Kevin D Mullen; Piero Amodio; Marsha Y Morgan
Journal:  Metab Brain Dis       Date:  2007-12       Impact factor: 3.584

7.  Effect of renal function impairment on the mortality of cirrhotic patients with hepatic encephalopathy: a population-based 3-year follow-up study.

Authors:  Tsung-Hsing Hung; Chih-Wei Tseng; Kuo-Chih Tseng; Yu-Hsi Hsieh; Chih-Chun Tsai; Chen-Chi Tsai
Journal:  Medicine (Baltimore)       Date:  2014-09       Impact factor: 1.889

8.  Proton pump inhibitors increase the severity of hepatic encephalopathy in cirrhotic patients.

Authors:  Matthew Fasullo; Prashanth Rau; Dong-Qi Liu; Erik Holzwanger; Jomol P Mathew; Yurima Guilarte-Walker; Gyongyi Szabo
Journal:  World J Hepatol       Date:  2019-06-27

9.  Erythromycin versus neomycin in the treatment of hepatic encephalopathy in cirrhosis: a randomized double-blind study.

Authors:  Fernando Gomes Romeiro; Fabio da Silva Yamashiro; Madileine Francely Américo; Luciana Aparecida Corá; Giovanni Faria Silva; José Ricardo de Arruda Miranda; Carlos Antonio Caramori
Journal:  BMC Gastroenterol       Date:  2013-01-16       Impact factor: 3.067

Review 10.  Step by Step: Managing the Complications of Cirrhosis.

Authors:  Irene C Perez; Fabian J Bolte; William Bigelow; Zachary Dickson; Neeral L Shah
Journal:  Hepat Med       Date:  2021-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.